Fate Therapeutics reports Q4 revenue $44.4M; ends Janssen deal, cuts workforce to ~220

FATE THERAPEUTICS INC

Cash and investments $441.2M plus $38.5M receivables; total ~$475M as of Dec 31, 2022.
Q4 2022 revenue $44.4M from collaborations; R&D expense $87.2M, G&A $21.6M.
Janssen collaboration terminated effective Apr 3, 2023; all programs discontinued.
Restructuring reduces headcount to ~220; expects $12-16M severance charges in Q1 2023.
IND planned mid-2023 for FT522 in B-cell lymphoma; FT825/ONO-8250 IND expected in 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

FATE THERAPEUTICS INC reported financial results for the fourth quarter and full year ended December 31, 2022.

Period: the fourth quarter and full year ended December 31, 2022
Result: reported results

Exact text from the filing

On February 28, 2023, Fate Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2022.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

FATE THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0000950170-23-005063

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.